Fig. 3
From: Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
HCC patient-derived MET-CAR-T cell activity in vitro. A MET-CAR-THCC cell transduction efficacy determined by flow cytometry using CD19 as a tag. B In vitro growth curves of MET-CAR-T cells derived from HS- or HCC patient-derived PBMCs. Results were averaged from independent HS and HCC (n = 4) with duplicates. Short bar refers to standard deviation. C, D MET-CAR-THCC cell killing activity against MHCC97H (n = 8) and C3A (n = 2) in vitro. For MHCC97H cells (C), results were averaged from 8 independent HCC cases. For C3A cells (D), 2 independent HCC cases were averaged. Triplicates were used for each experiment. Bracketed bar refers to standard deviation